Q2 2024

Source filing unavailable

Q2 2024 · —

Revenue—

Net Income

$3.25B

+40.2% vs Q2 2023

EPS Diluted

$1.59

+43.2% vs Q2 2023

Gross Profit$9,699,000,000+1.1%

Operating Income$4,014,000,000+37.5%

Operating Cash Flow$4,875,000,000+36.3%

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Net Income	$3.25B	$2.32B	$1.69B	$2.90B
EPS Diluted	$1.59	$1.11	$0.77	$1.28

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Novartis AG · CIK 1114448 · Engraved from SEC EDGAR